20.06.2024 | ASO Author Reflections
ASO Author Reflections: Contralateral Axillary Metastasis in Breast Cancer: Prognostic Variability and Benefits of Surgical Treatment
verfasst von:
Ji-Jung Jung, MD, MS, Hyeong-Gon Moon, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2024
Einloggen, um Zugang zu erhalten
Excerpt
Contralateral axillary lymph node metastasis (CAM) refers to the extra axillary spread of cancer cells from the primary breast tumor to the contralateral axillary lymph node and is currently classified as metastatic, stage IV disease. Nevertheless, studies on CAM have shown that a majority of patients are being surgically treated with curative intent rather than a palliative approach.
1 Moreover, the reported overall survival (OS) for CAM varies substantially: OS described in earlier studies ranged between 33 and 71% with median follow-up periods of 24–35 months, but more recent larger studies by Magnoni et al. and Zhang et al., each with fewer than 60 patients, showed much improvement to 5-year OS of 67.4–72%.
2,3 Based on these findings, some authors question the current staging of CAM as a stage IV disease and suggest reclassification to stage III breast cancer, similar to ipsilateral supraclavicular metastasis.
4 However, due to the small number of reported cases, the question still remains unanswered. …